Conference Call with Divi's Laboratories Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals firm Divi's Laboratories declares Q4FY22 result: Divi's Labs earns a Revenue of Rs 9074 crores for FY22 on a consolidated basis. Divi's Laboratories has earned a consolidated total revenue of Rs 9074 crores for the financial year 2021-22 as against Rs 7032 crores during the previous year, reflecting a growth of 29%. PBT for the current year grew by 38% to Rs 3684 crores as against a PBT of Rs 2666 crores for the previous year. PAT for the year amounted to Rs 2960 crores as against a PAT of Rs 1984 crores for the last year, reflecting a growth of 49%. Result PDF